Alpharma Inc. (ALO) Closes Transaction to License U.S. Rights for Prescription Topical NSAID Pain Drug
10/12/2007 11:17:21 AM
BRIDGEWATER, NJ--(Marketwire - October 12, 2007) - Alpharma Inc. (NYSE: ALO) today announced its affiliate, Alpharma Ireland Limited, has closed its previously announced agreement with IDEA AG ("IDEA"), a privately held biopharmaceutical company with headquarters in Munich, Germany, to license the exclusive United States rights to ketoprofen in Transfersome® gel, a prescription topical NSAID (non-steroidal anti-inflammatory drug) in Phase III clinical development. This license includes access to IDEA's innovative Transfersome® technology platform that delivers drugs locally to targeted areas.
comments powered by